FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2005805770> ?p ?o ?g. }

• W2005805770 endingPage "276" @default.
• W2005805770 startingPage "265" @default.
• W2005805770 abstract "Donor lymphocyte infusion (DLI), pioneered in Jerusalem in January 1987, represents the first proof of principle of the absolute efficacy of immunotherapy as a means of curing cancer. Immunotherapy with alloreactive donor lymphocytes can eliminate the last tumor cell even in patients with hematological malignancies resistant to maximally tolerated doses of chemoradiotherapy. Alloreactive lymphocytes that can mediate anti-tumor effects following induction of host-versus-graft tolerance induced by transplantation of donor stem cells, can induce graft-versus-malignancy (GVM) effects which are usually accompanied by graft-versus-host disease (GVHD). However, occasionally GVM effects may also be accomplished independently of clinically overt GVHD. Interestingly, allogeneic donor lymphocytes may also eliminate undesirable host-derived hematopoietic cells in a large number of nonmalignant indications including genetic diseases, diseases caused by deficiency of stem cell products, and autoimmune disorders mediated by self-reactive lymphocytes. The cumulative clinical experience suggests feasibility of effective induction of graft-versus-leukemia (GVL); graft-versus-lymphoma (GVLy); graft-versus-multiple myeloma, as well as graft-versus-solid tumors (GVT), well-documented in patients with renal and breast cancer, even in patients with resistant disease that have failed myeloablative chemoradiotherapy. These observations that suggested that cell therapy by donor lymphocytes is the main therapeutic benefit of bone marrow transplantation (BMT) led to development of the nonmyeloablative approach for safer allogeneic stem cell transplantation. Nonmyeloablative stem cell transplantation (NST) makes it possible to offer an option for cure to elderly patients with no upper age limit, as well as to patients with poor performance status not considered eligible for conventional BMT. Using well-tolerated NST regimen, allogeneic stem cell transplantation can be accomplished with minimal procedure-related toxicity and mortality, possibly even on an outpatient basis. Immunotherapy mediated by adoptive allogeneic cell-mediated immunotherapy can be further improved by utilizing specifically immune donor lymphocytes, thus maximizing their efficacy against undesirable target cells of host origin on the one hand, while minimizing their ontoward efficacy against normal cells of host origin that could result in GVHD on the other. Taken together, DLI and subsequently NST, may have opened new horizons for treatment of life-threatening malignant and nonmalignant disorders correctable by allogeneic stem cell transplantation. It is anticipated that further improvement of reactivity and specificity of donor lymphocytes will lead to safer clinical application of cell therapy for a larger number of indications toward improving disease-free survival in a large number of indications while minimizing immediate and late procedure-related complications." @default.
• W2005805770 created "2016-06-24" @default.
• W2005805770 creator A5030282008 @default.
• W2005805770 creator A5059915616 @default.
• W2005805770 creator A5066233734 @default.
• W2005805770 creator A5067581165 @default.
• W2005805770 date "2002-04-01" @default.
• W2005805770 modified "2023-09-30" @default.
• W2005805770 title "Donor Lymphocyte Infusion: The Use of Alloreactive and Tumor-Reactive Lymphocytes for Immunotherapy of Malignant and Nonmalignant Diseases in Conjunction with Allogeneic Stem Cell Transplantation" @default.
• W2005805770 cites W1274344746 @default.
• W2005805770 cites W1444462873 @default.
• W2005805770 cites W1479909146 @default.
• W2005805770 cites W1545991364 @default.
• W2005805770 cites W1575533059 @default.
• W2005805770 cites W1585270289 @default.
• W2005805770 cites W1707184873 @default.
• W2005805770 cites W1873141201 @default.
• W2005805770 cites W1883328448 @default.
• W2005805770 cites W1912762949 @default.
• W2005805770 cites W1963624862 @default.
• W2005805770 cites W1965725959 @default.
• W2005805770 cites W1976183578 @default.
• W2005805770 cites W1981715129 @default.
• W2005805770 cites W1986288858 @default.
• W2005805770 cites W1992401639 @default.
• W2005805770 cites W1995678692 @default.
• W2005805770 cites W1997015090 @default.
• W2005805770 cites W2001499325 @default.
• W2005805770 cites W2003978399 @default.
• W2005805770 cites W2007905422 @default.
• W2005805770 cites W2010838282 @default.
• W2005805770 cites W2018244870 @default.
• W2005805770 cites W2019215987 @default.
• W2005805770 cites W2022584463 @default.
• W2005805770 cites W2022682658 @default.
• W2005805770 cites W2065055879 @default.
• W2005805770 cites W2067480394 @default.
• W2005805770 cites W2071167148 @default.
• W2005805770 cites W2076636340 @default.
• W2005805770 cites W2079365532 @default.
• W2005805770 cites W2082262118 @default.
• W2005805770 cites W2082622575 @default.
• W2005805770 cites W2087653021 @default.
• W2005805770 cites W2087817425 @default.
• W2005805770 cites W2108782166 @default.
• W2005805770 cites W2117581174 @default.
• W2005805770 cites W2120756704 @default.
• W2005805770 cites W216764306 @default.
• W2005805770 cites W2176120669 @default.
• W2005805770 cites W2226146977 @default.
• W2005805770 cites W2255034921 @default.
• W2005805770 cites W2267293668 @default.
• W2005805770 cites W2297816245 @default.
• W2005805770 cites W2300937173 @default.
• W2005805770 cites W2313520573 @default.
• W2005805770 cites W2318099690 @default.
• W2005805770 cites W2325341505 @default.
• W2005805770 cites W2325605534 @default.
• W2005805770 cites W2327695677 @default.
• W2005805770 cites W2327912446 @default.
• W2005805770 cites W2396781079 @default.
• W2005805770 cites W2400663726 @default.
• W2005805770 cites W309638826 @default.
• W2005805770 cites W3112391182 @default.
• W2005805770 cites W4246085869 @default.
• W2005805770 cites W44995847 @default.
• W2005805770 doi "https://doi.org/10.1089/152581602753658457" @default.
• W2005805770 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11983098" @default.
• W2005805770 hasPublicationYear "2002" @default.
• W2005805770 type Work @default.
• W2005805770 sameAs 2005805770 @default.
• W2005805770 citedByCount "51" @default.
• W2005805770 countsByYear W20058057702012 @default.
• W2005805770 countsByYear W20058057702013 @default.
• W2005805770 countsByYear W20058057702015 @default.
• W2005805770 countsByYear W20058057702017 @default.
• W2005805770 countsByYear W20058057702018 @default.
• W2005805770 countsByYear W20058057702019 @default.
• W2005805770 countsByYear W20058057702021 @default.
• W2005805770 countsByYear W20058057702023 @default.
• W2005805770 crossrefType "journal-article" @default.
• W2005805770 hasAuthorship W2005805770A5030282008 @default.
• W2005805770 hasAuthorship W2005805770A5059915616 @default.
• W2005805770 hasAuthorship W2005805770A5066233734 @default.
• W2005805770 hasAuthorship W2005805770A5067581165 @default.
• W2005805770 hasConcept C121608353 @default.
• W2005805770 hasConcept C126322002 @default.
• W2005805770 hasConcept C203014093 @default.
• W2005805770 hasConcept C2777408962 @default.
• W2005805770 hasConcept C2777701055 @default.
• W2005805770 hasConcept C2779695342 @default.
• W2005805770 hasConcept C2779972918 @default.
• W2005805770 hasConcept C28328180 @default.
• W2005805770 hasConcept C2911091166 @default.
• W2005805770 hasConcept C54355233 @default.
• W2005805770 hasConcept C71924100 @default.
• W2005805770 hasConcept C86803240 @default.
• W2005805770 hasConcept C8891405 @default.

• next